Literature DB >> 30362298

Network pharmacology-based prediction of the active ingredients, potential targets, and signaling pathways in compound Lian-Ge granules for treatment of diabetes.

Jintao Xue1, Yongli Shi1, Chunyan Li1,2, Huijie Song1.   

Abstract

AIMS: Compound Lian-Ge granules (CLGGs) is a traditional Chinese medicine preparation with good hypoglycemic effect and health function. This study was to predict its active ingredients, potential targets, signaling pathways, and investigate its mechanism of "ingredient-targets-pathways."
METHODS: Pharmacodynamics studies on diabetic rats showed that CLGGs had an obvious hypoglycemic effect. On this basis, 27 hypoglycemic active ingredients were screened out. Their targets were confirmed by comparing with these hypoglycemic targets in PharmMapper and DrugBank databases via reversed pharmacophore matching approach. The relationships between ingredients and targets were revealed by comparing data in the String database. A network of "ingredient-target-passageway" was constructed.
RESULTS: Studies showed that CLGGs had 24 active ingredients, ie, berberine, puerarin, danshinolic acid A, and sinigrin, etc. These ingredients involved nine targets, ie, insulin-like growth factor 1 receptor, insulin-degrading enzyme, ɑ-amylase, and so on, and 111 metabolic pathways, eg, hypoxia-inducible factor 1 signaling pathway, PI3K-Akt signaling pathway, mammalian target of rapamycin signaling pathway, and FoxO signaling pathway.
CONCLUSION: Using network pharmacology methods, this study predicted the hypoglycemic active ingredients in CLGGs and revealed their targets, and provided a clue for further exploration of the hypoglycemic mechanism of CLGGs.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  active ingredients; network pharmacology; reverse pharmacophore matching; signaling pathways; targets

Mesh:

Substances:

Year:  2018        PMID: 30362298     DOI: 10.1002/jcb.27933

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Lupenone is a good anti-inflammatory compound based on the network pharmacology.

Authors:  Feng Xu; Liubo Yang; Xulong Huang; Yuqing Liang; Xiangpei Wang; Hongmei Wu
Journal:  Mol Divers       Date:  2019-02-22       Impact factor: 2.943

2.  Prediction of Targets of Curculigoside A in Osteoporosis and Rheumatoid Arthritis Using Network Pharmacology and Experimental Verification.

Authors:  Jiawen Han; Minjie Wan; Zhanchuan Ma; Cong Hu; Huanfa Yi
Journal:  Drug Des Devel Ther       Date:  2020-11-26       Impact factor: 4.162

3.  Identification of phytochemicals from North African plants for treating Alzheimer's diseases and of their molecular targets by in silico network pharmacology approach.

Authors:  Karim Raafat
Journal:  J Tradit Complement Med       Date:  2020-08-12

4.  Anti-Alzheimer's Disease Molecular Mechanism of Acori Tatarinowii Rhizoma Based on Network Pharmacology.

Authors:  Yujia Zhang; Yangshen Wu; Yunbo Fu; Luning Lin; Yiyou Lin; Yehui Zhang; Liting Ji; Changyu Li
Journal:  Med Sci Monit Basic Res       Date:  2020-06-01

5.  Anti-Lung Cancer Targets of Radix Paeoniae Rubra and Biological Molecular Mechanism: Network Pharmacological Analyses and Experimental Validation.

Authors:  Yunfei Ma; Guangda Li; Mingwei Yu; Kexin Cao; Qiwei Li; Xu Sun; Guowang Yang; Xiaomin Wang
Journal:  Onco Targets Ther       Date:  2021-03-16       Impact factor: 4.147

6.  Prediction of the Mechanisms by Which Quercetin Enhances Cisplatin Action in Cervical Cancer: A Network Pharmacology Study and Experimental Validation.

Authors:  Huihui Ji; Kehan Li; Wenbin Xu; Ruyi Li; Shangdan Xie; Xueqiong Zhu
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

7.  Network pharmacology and RNA sequencing studies on triterpenoid saponins from Bupleurum chinense for the treatment of breast cancer.

Authors:  Danqi Li; Da Liu; Dandan Yue; Pinyi Gao; Cheng Du; Xuegui Liu; Lixin Zhang
Journal:  RSC Adv       Date:  2019-12-12       Impact factor: 4.036

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.